Trial Profile
A Pilot Study of CPI-613 in Patients With Myelodysplastic Syndrome Who Have Failed Previous Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2021
Price :
$35
*
At a glance
- Drugs Devimistat (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 01 Jul 2021 Status changed from completed to discontinued.
- 28 Jun 2021 Status changed from suspended to completed.
- 26 Feb 2021 Planned End Date changed from 1 Mar 2021 to 1 May 2021.